Cardiotoxicity Testing
Cardiotoxicity Testing - Related Videos
04:47
Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity
0 Views •
2023
This video describes the technique of creating a zebrafish cardiomyopathy model with minimal variations among experimental groups and in the sample, we create zebrafish cardiomyopathy model using the drug doxorubicin.
11:00
Using Chicken Embryo as a Powerful Tool in Assessment of Developmental Cardiotoxicities
0 Views •
Cited by 2 •
2021
Chicken embryos, as a classical developmental model, are used in our lab to assess developmental cardiotoxicities following exposure to various environmental contaminants. Exposure methods and morphological/functional assessment methods established are described in this manuscript.
07:47
Anxiety Testing
0 Views •
2023
Anxiety is a commonly observed behavioral disorder that stems from fear. It is described as increased restlessness, or unpleasant feelings of fear over anticipated events. Experimenters often use rodent models to better understand anxiety disorders in humans. They use different paradigms, like exposing rodents to bright spaces or loud sounds, which are known to induce fear. These tests combined with other interventions such as surgery or drug-administration may assist researchers in pinpointing...
11:08
Tests on Wood
0 Views •
2023
Source: Roberto Leon, Department of Civil and Environmental Engineering, Virginia Tech, Blacksburg, VA Wood is a ubiquitous material that has been used in construction from the earliest times. Wood is a renewable, sustainable material with great aesthetic value. Today, there are probably more buildings constructed with wood than any other structural material. Many of these buildings are singlefamily residences, but many larger apartment buildings, as well as commercial and industrial buildings,...
07:17
Pilot Testing
0 Views •
2023
Source: Laboratories of Gary Lewandowski, Dave Strohmetz, and Natalie Ciarocco—Monmouth University In any experiment researchers have the challenge of creating experiences for participants that are consistent (i.e., reliable) and authentic (i.e., valid). Yet there are many ways to manipulate any one variable. For example, if you want participants to feel sad, you can have them think of their own sad memory, watch a sad video, or read a sad story. Researchers must find the best way to...
FAQs
A meaningful assessment separates electrical disturbances from impaired contraction, reduced cardiomyocyte viability, and measurable cellular injury. These endpoints describe different aspects of cardiac function, so a treatment may produce an abnormal rhythm signal without the same pattern of contractile or viability changes. Distinguishing them helps investigators characterize the nature and extent of a potential hazard.
Each approach captures a different level of cardiac response. Electrocardiography examines electrical activity, imaging evaluates structural or functional changes, biomarkers indicate injury, and cardiomyocyte assays provide controlled information about cell viability or contractility. Using complementary methods can reveal effects that one measurement alone might miss and supports a more complete interpretation of treatment-related cardiovascular risk.
Dose-related changes help connect the amount of a drug, treatment, or chemical with the severity or likelihood of an observed cardiac effect. This relationship can clarify whether findings become more pronounced as exposure increases and can support early decisions about safety. The resulting evidence contributes to risk management and helps guide further evaluation of potentially harmful therapies.
A workflow may begin with controlled in vitro assessment of cardiomyocytes, followed by measurements of viability, contractility, or injury. Electrocardiography, cardiac imaging, and biomarker analysis can then add functional or clinical information at appropriate evaluation stages. Interpreting these results together helps identify concerning effects, examine dose-related responses, and determine whether additional safety assessment is warranted.
The testing is relevant across drug discovery, preclinical safety evaluation, clinical monitoring, and risk management. Early studies can identify concerning responses before development advances, while later assessments help track cardiovascular effects during treatment. Applying the methods at multiple stages supports decisions about a therapy's safety profile and provides information that can inform safer treatment choices.
Results can show whether a therapy is associated with altered rhythm, impaired contractility, reduced cell viability, or evidence of cardiac injury. They can also clarify how responses change with dose and whether different assessment methods point to a consistent concern. These findings support cardiovascular safety evaluation, clinical monitoring, and the development of more predictive testing models.